Person: SOYSAL, PINAR
Now showing 1 - 10 of 260
- PublicationOpen AccessMild cognitive impairment is associated with fall-related injury among adults aged ≥65 years in low- and middle-income countries.(2020-12-29T00:00:00Z) Smith, Lee; Jacob, Louis; Kostev, Karel; Butler, Laurie; Barnett, Yvonne; Pfeifer, Briona; Soysal, PINAR; Grabovac, Igor; López-Sánchez, Guillermo F; Veronese, Nicola; Yang, Lin; Oh, Hans; Koyanagi, Ai; SOYSAL, PINAR
- PublicationOpen AccessThe Association Between Sedentary Behavior and Sarcopenia Among Adults Aged >= 65 Years in Low- and Middle-Income Countries(2020-03-01T00:00:00Z) Smith, Lee; Tully, Mark; Jacob, Louis; Blackburn, Nicole; Adlakha, Deepti; Caserotti, Paolo; SOYSAL, PINAR; Veronese, Nicola; Lopez Sanchez, Guillermo F.; Vancampfort, Davy; Koyanagi, Ai; SOYSAL, PINARThe present study aimed to assess the association between sedentary behavior and sarcopenia among adults aged >= 65 years. Cross-sectional data from the Study on Global Ageing and Adult Health were analyzed. Sarcopenia was defined as having low skeletal muscle mass and either a slow gait speed or a weak handgrip strength. Self-reported sedentary behavior was assessed as a continuous variable (hours per day) and also as a categorical variable (0-= 11 hours/day). Multivariable logistic regression was conducted to assess the association between sedentary behavior and sarcopenia. Analyses using the overall sample and country-wise samples were conducted. A total of 14,585 participants aged >= 65 years were included in the analysis. Their mean age was 72.6 (standard deviation, 11.5) years and 55% were females. Compared to sedentary behavior of 0-= 11 hours/day was significantly associated with 2.14 (95% CI = 1.06-4.33) times higher odds for sarcopenia. The country-wise analysis showed that overall, a one-hour increase in sedentary behavior per day was associated with 1.06 (95% CI = 1.04-1.10) times higher odds for sarcopenia, while the level of between-country heterogeneity was low (I-2 = 12.9%). Public health and healthcare practitioners may wish to target reductions in sedentary behavior to aid in the prevention of sarcopenia in older adults.
- PublicationMetadata onlyWhich Cholinesterase Inhibitor is the Safest for the Heart in Elderly Patients With Alzheimer-s Disease?(2012-05-01T00:00:00Z) ISIK, Ahmet Turan; BOZOGLU, Ergun; YAY, Adnan; Soysal, PINAR; ATESKAN, Umit; SOYSAL, PINARObjective: Cholinesterase inhibitors (ChEIs) are widely used for the treatment of Alzheimer-s disease (AD); however, their cholinergic side effects on the cardiovascular system are still unclear. In this study, we aimed to examine the side effects caused by donepezil, rivastigmine, and galantamine on cardiac rhythm and postural blood pressure changes in elderly patients with AD. Methods: Of 204 consecutive elderly patients who were newly diagnosed with AD, 162 were enrolled and underwent comprehensive geriatric assessments. The electrocardiographs (ECGs) and blood pressures were recorded at the baseline and 4 weeks after the dose of 10 mg/d of donepezil, 10 cm2/d of rivastigmine, and 24 mg/d of galantamine. Results: There were no changes relative to the baseline in any of the ECG parameters or arterial blood pressure with any of the administered ChEIs. Conclusion: It was demonstrated that none of the 3 ChEIs were associated with increased negative chronotropic, arrhythmogenic, and hypotensive effects for the elderly patients with AD.
- PublicationMetadata onlyInvestigation of optimum hemoglobin levels in older patients with chronic kidney disease.(2022-09-22T00:00:00Z) Kara, O; Soysal, P; Kiskac, M; Smith, L; Karışmaz, A; Kazancioglu, Rümeyza; SOYSAL, PINAR; KAZANCIOĞLU, RÜMEYZA
- PublicationMetadata onlyPhysical multimorbidity and incident urinary incontinence among community-dwelling adults aged ≥50 years: findings from a prospective analysis of the Irish Longitudinal Study on Ageing.(2021-07-17T00:00:00Z) Smith, Lee; Shin, Jae Il; Ghayda, Ramy Abou; Hijaz, Adonis; Sheyn, David; Pope, Rachel; Hong, Sun Hwi; Kim, Sung Eun; Ilie, Petre Cristian; Carrie, Anne Marie; Ippoliti, Simona; Soysal, PINAR; Barnett, Yvonne; Pizzol, Damiano; Koyanagi, Ai; SOYSAL, PINAR
- PublicationOpen AccessAn umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of hydroxychloroquine and chloroquine therapy.(2020-12-11T00:00:00Z) Celotto, Stefano; Veronese, Nicola; Barbagallo, Mario; Ometto, Francesca; Smith, Lee; Pardhan, Shahina; Barnett, Yvonne; Ilie, Petre Cristian; Soysal, PINAR; Lagolio, Erik; Kurotschka, Peter Konstantin; Tonelli, Roberto; Demurtas, Jacopo; SOYSAL, PINARBackground & aims: Hydroxychloroquine (HCQ) and chloroquine (CQ) are anti-malarial drugs frequently used in the rheumatologic field. They were recently identified as potential therapeutic options for Coronavirus Disease (COVID-19). The present study aims to map and grade the diverse health outcomes associated with HCQ/CQ using an umbrella review approach. Methods: Umbrella review of systematic reviews of observational and intervention studies. For observational studies, random-effects summary effect size, 95% confidence interval, and 95% prediction interval were estimated. We also assessed heterogeneity, evidence for small-study effect, and evidence for excess significance bias. The quality of evidence was then graded using validated criteria from highly convincing to weak. The evidence from randomized controlled trials (RCTs) was graded using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) tool. Results: From 313 articles returned in the literature search, six meta-analyses were included (n = 25 outcomes). Among meta-analyses (MAs) of observational studies, HCQ/CQ are weakly associated with a reduced risk for cardiovascular events and diabetes when used for autoimmune diseases and with spontaneous abortion; they are also associated with a higher risk of death in COVID-19 patients. Among MAs of RCTs, HCQ/CQ are associated with an improvement of articular manifestations of rheumatic diseases. Conclusions: There is high evidence of the efficacy of HCQ/CQ in the rheumatologic field. The lack of evidence for efficacy and the risk of death associated with the use of HCQ/CQ for COVID-19 indicate the inappropriateness of their inclusion in recent COVID-19 therapy guidelines and the urgent need for RCTs to determine eventual appropriateness as a COVID-19 therapy. Keywords: COVID-19; Chloroquine; Hydroxychloroquine; umbrella review.
- PublicationMetadata onlyPrevalence of depressive symptoms in elderly cancer patients receiving chemotherapy and influencing factors.(2018-09-01T00:00:00Z) ATAG, E; MUTLAY, F; Soysal, PINAR; SEMIZ, HS; KAZAZ, SN; KESER, M; ELLIDOKUZ, H; KARAOGLU, A; SOYSAL, PINAR
- PublicationMetadata onlyCorrigendum to -Inflammation and frailty in the elderly: A systematic review and meta-analysis- [Ageing Res Rev. 31 (2016) 1-8].(2017-05-01T00:00:00Z) Soysal, PINAR; STUBBS, B; LUCATO, P; LUCHINI, C; SOLMI, M; PELUSO, R; SERGI, G; ISIK, AT; MANZATO, E; MAGGI, S; MAGGIO, M; PRINA, AM; COSCO, TD; WU, YT; VERONESE, N; SOYSAL, PINAR
- PublicationMetadata onlyCutoff point of waist circumference for the diagnosis of metabolic syndrome in Turkish population(2011-10-18) HURSITOGLU, MEHMET; TUKEK, TUFAN; CIKRIKCIOGLU, MEHMET ALI; YIGIT, YILDIZ; CAKIRCA, MUSTAFA; ZEREN, GUZIN; APIKOGLU, S RABUS; KARA, OSMAN; CORDAN, ILKER; YETMIS, MIKAIL; SOYSAL, PINAR; ÇAKIRCA, MUSTAFA; SOYSAL, PINAR
- PublicationMetadata onlyUric acid may be protective against cognitive impairment in older adults, but only in those without cardiovascular risk factors.(2017-03-01T00:00:00Z) TUVEN, B; Soysal, PINAR; UNUTMAZ, G; KAYA, D; ISIK, AT; SOYSAL, PINAR